PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma

Introduction Intratumoral administration of pexa-vec (Pexastimogene Devacirepvec), an oncolytic and immunotherapeutic vaccinia virus. given to patients with hepatocellular carcinoma (HCC), is associated with both local and distant tumor responses. We hypothesized subsequent treatment with sorafenib...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Ghassan K. Abou-Alfa, Peter R. Galle, Yee Chao, Joseph Erinjeri, Jeong Heo, Mitesh J. Borad, Angelo Luca, James Burke, Adina Pelusio, Delphine Agathon, Monika Lusky, Caroline Breitbach, Shukui Qin, Edward Gane
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Karger Publishers 2023-09-01
coleção:	Liver Cancer
Acesso em linha:	https://beta.karger.com/Article/FullText/533650
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!